Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around
Principal Investigator
by Ryan Broderick, MD (ucsd)
Headshot of Ryan Broderick
Ryan Broderick

Description

Summary

A prospective, retrospective, non-randomized, multicenter study with two independent hernia study cohorts (Ventral / Incisional Hernia Repair and Diaphragmatic / Hiatal Hernia Repair). The primary objective of this study is to collect GORE® ENFORM Biomaterial product commercial-use data on device functional performance.

Official Title

GORE® ENFORM Biomaterial Product Study: A Study to Describe Multi-use Biomaterial Performance in Hernia Patients

Keywords

Hernia, Ventral, Hernia, Hiatal, Hernia, Diaphragmatic, Incisional Hernia, hernia, ventral, hiatal, diaphragmatic, incisional, mesh, Gore, W.L. Gore, Enform, Ventral Hernia, Diaphragmatic Hernia, Hiatal Hernia, Gore ENFORM Biomaterial (Preperitoneal), Gore ENFORM Biomaterial (Intraperitoneal), Ventral/Incisional Hernia - Preperitoneal ENFORM Biomaterial, Ventral/Incisional Hernia - Intraperitoneal ENFORM Biomaterial, Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM Biomaterial, Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM Biomaterial

Eligibility

For people ages 18 years and up

Pre-procedure Inclusion Criteria:

The subject is / has:

  1. At least 18 years old at the time of informed consent. Minimum age required by state regulations (as applicable).
  2. An expected scored Class I (Clean) surgical wound using CDC Surgical Wound Classification system.
  3. A planned implant with GORE® ENFORM Biomaterial for a single site ventral or hiatal hernia repair as suture line reinforcement.
  4. An expected scored Grade 1 or Grade 2 using the Ventral Hernia Working Group Grading system.
  5. Willing to provide informed consent and comply with follow-up requirements.

Pre-procedure Exclusion Criteria:

The subject is / has:

  1. Treated in another drug or medical device study within 1 year of study enrollment.
  2. Implanted with GORE® ENFORM Biomaterial in the reconstruction of cardiovascular defects.
  3. Hernia repair expected to be performed as part of a bridged procedure (i.e., expected inability to perform primary closure of fascia or crura, patients requiring permanent support from the device).
  4. A BMI >40.
  5. Evidence of a systemic infection.
  6. Cirrhosis or undergoing dialysis.
  7. A wound-healing disorder.
  8. Immunocompromised such as, with HIV or transplant, or receiving chemo or radiation therapy.
  9. Expected to undergo mesh implantation in conjunction with any bariatric procedure and / or panniculectomy procedure.
  10. A stoma.
  11. Co-morbid conditions that may limit their ability to comply with study and follow-up requirements.
  12. Positive pregnancy or lactation status as confirmed by site standard of care.
  13. Hernias requiring treatment within multiple body regions or expected use of multiple hernia mesh devices.

Post-procedure Inclusion Criteria

At the time of index procedure, the subject is / has:

  1. At least 18 years old. Minimum age required by state regulations (as applicable).
  2. Implanted with GORE® ENFORM Biomaterial for a single site ventral or hiatal hernia repair as suture-line reinforcement on or before 365 days prior to site protocol amendment 3 approval date.
  3. Unless there is an Informed Consent waiver issued by the Institutional Review Board (IRB), an Informed Consent Form (ICF) signed by subject.

Post-procedure Exclusion Criteria

At the time of index procedure, the subject is / has:

  1. Treated in another drug or medical device study within 1 year of study enrollment.
  2. Implanted with GORE® ENFORM Biomaterial in the reconstruction of cardiovascular defects.
  3. Hernia repair that was performed as part of a bridged procedure (i.e., inability to perform primary closure of fascia or crura, patients requiring permanent support from the device).
  4. A BMI >40.
  5. Evidence of a systemic infection.
  6. Cirrhosis or undergoing dialysis.
  7. A wound-healing disorder.
  8. Immunocompromised such as, with HIV or transplant, or receiving chemo or radiation therapy.
  9. Underwent mesh implantation in conjunction with any bariatric procedure and / or panniculectomy procedure.
  10. A stoma.
  11. Co-morbid conditions that may limit their ability to comply with study and follow-up requirements.
  12. Positive pregnancy or lactation status as confirmed by site standard of care.
  13. Hernias requiring treatment within multiple body regions or expected use of multiple hernia mesh devices.

Locations

  • University of California - San Diego accepting new patients
    San Diego California 92093 United States
  • Institute of Esophageal and Reflux Surgery in progress, not accepting new patients
    Denver Colorado 80124 United States
  • University of Texas Health Science Center at Houson accepting new patients
    Houston Texas 77401 United States

Lead Scientist at University of California Health

  • Ryan Broderick, MD (ucsd)
    Associate Professor Of Clinical, Surgery, Vc-health Sciences-schools

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
W.L.Gore & Associates
ID
NCT04718168
Study Type
Interventional
Participants
Expecting 245 study participants
Last Updated